

Alexander J Lepak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2059454/publications.pdf>

Version: 2024-02-01

39
papers

938
citations

471509

17
h-index

454955

30
g-index

40
all docs

40
docs citations

40
times ranked

1289
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an <i>In Vivo</i> Murine Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1265-1272.	3.2	83
2	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Biorganic and Medicinal Chemistry</i> , 2016, 24, 6390-6400.	3.0	79
3	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	71
4	Pharmacodynamic Optimization for Treatment of Invasive <i>Candida auris</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	65
5	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against <i>Candida</i> spp. in a Neutropenic Disseminated Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	56
6	Pharmacodynamic Evaluation of Rezafungin (CD101) against <i>Candida auris</i> in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	56
7	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	48
8	<i>In Vivo</i> Pharmacodynamic Target Assessment of Delafloxacin against <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i> , and <i>Klebsiella pneumoniae</i> in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4764-4769.	3.2	44
9	Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel. <i>Clinical Infectious Diseases</i> , 2021, 73, e1329-e1336.	5.8	43
10	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Streptococcus pneumoniae</i> in the Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
11	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	37
12	<i>In Vivo</i> Pharmacodynamic Target Assessment of Eravacycline against <i>Escherichia coli</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	35
13	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1258-1264.	3.2	32
14	<i>In Vivo</i> Pharmacodynamics of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
15	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	24
16	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 783-794.	2.1	22
17	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	22
18	Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2021, 181, 1399.	5.1	19

#	ARTICLE	IF	CITATIONS
19	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo- β -Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
20	Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
21	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
22	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	3.0	13
23	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	11
24	In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 258-260.	1.8	10
25	<i>In Vivo</i> Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	9
26	<i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	9
27	In Vivo Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	8
28	Implementation of infection control measures to prevent healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 229-232.	1.8	8
29	COVID-19 in Health Care Personnel. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2312-2322.	3.0	8
30	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2256-2264.	1.0	4
31	Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Academic Center in a Low-Prevalence Area of the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa388.	0.9	3
32	The Wrong Frame of Mind. <i>New England Journal of Medicine</i> , 2018, 378, 1716-1721.	27.0	2
33	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
34	Pharmacodynamic Optimization for the Treatment of Invasive <i>Candida auris</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S73-S73.	0.9	1
35	Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 356-370.	1.9	1
36	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against <i>S. aureus</i> (SA) and <i>S. pneumoniae</i> (SPN). <i>Open Forum Infectious Diseases</i> , 2018, 5, S426-S426.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Clinical utility of dual anterior nares and oropharynx MRSA screening polymerase chain reaction assay (PCR) for patients with suspected pneumonia. Infection Control and Hospital Epidemiology, 2021, , 1-3.	1.8	1
38	Reply to Maziade et al. Clinical Infectious Diseases, 2021, 73, 1548.	5.8	0
39	Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia " ERRATUM. Infection Control and Hospital Epidemiology, 2021, , 1-1.	1.8	0